Augtyro
Indication

AUGTYRO (repotrectinib) is an oral prescription medicine used to treat adults and children 12 years and older with solid tumors (cancer) that are caused by certain abnormal NTRK genes, and have spread to other parts of the body or if surgery to remove your cancer is likely to cause severe complications, and have grown or spread after any other treatment or there is no satisfactory alternative treatment option.

It is not known if AUGTYRO is safe and effective in children younger than 12 years of age with NTRK-positive solid tumors.

AUGTYRO® (repotrectinib) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread within your chest or to other parts of the body and is caused by an abnormal ROS1 gene.

It is not known if AUGTYRO is safe and effective in children with ROS1-positive NSCLC.

Close X

BACK

Pricing Information

Like many patients, knowing what you may pay for treatment can be a major concern. That's why Bristol Myers Squibb (BMS) is committed to helping you understand your out-of-pocket (OOP) costs and possible resources that may help make them more affordable.

The list price of AUGTYRO is $30,740 when given as 160 mg twice daily for 30 days.* Most patients with prescription coverage will pay less.

  • lf you have commercial insurance

    You could pay as little as $0 per month up to a maximum benefit of $15,000 per calendar year with the BMS Co-pay Assistance Program.

    Learn more about this program.
  • If you have Medicare

    For AUGTYRO, your costs are determined by your pharmacy coverage such as Medicare Part D or Medicare Advantage (a.k.a., Part C), your coverage phase, and your income level. Use this link to learn about costs for Medicare drug coverage. Please check with your Medicare plan administrator for more details and to understand your specific costs.

  • If you have Medicaid

    To find out if you qualify for Medicaid or to get more information about whether co-payments or other cost-sharing may apply in your state, please use this link to visit the Medicaid website or contact your state Medicaid program.

  • lf you do not have insurance coverage

    If you do not have coverage for AUGTYRO, you can expect to pay the list price shown above, along with any additional pharmacy charges, less any available discounts, based on where you purchase your prescription medicine.

  • For additional Information, BMS Access Support® can provide resources to help patients understand their insurance coverage and find information on sources of financial support.

    Eligible commercially insured patients may pay as little as $0 per one-month supply (subject to an out of pocket maximum).

    Please visit BMS Access Support or call 1-800-861-0048, 8AM–8PM ET, Monday–Friday.

    Additional eligibility requirements and terms and conditions apply. Please click here for full terms and conditions.

*As of November 2024, for a 30 day supply. List price is also known as wholesale acquisition cost, or WAC. WAC is the price at which pharmaceutical manufacturers sell their products to wholesalers. Most people do not pay list price for AUGTYRO.

BMS does not guarantee reimbursement and it is the HCP's responsibility to be accurate.

BACK

INDICATION

AUGTYRO® (repotrectinib) is a prescription medicine used to treat:

  • adults with non-small cell lung cancer (NSCLC) that has spread within your chest or to other parts of the body and is caused by an abnormal ROS1 gene.
  • adults and children 12 years of age and older with solid tumors (cancer) that:
    • are caused by certain abnormal NTRK genes, and
    • have spread to other parts of the body, or if surgery to remove your cancer is likely to cause severe complications, and
    • have grown or spread after other treatment or there is no satisfactory alternative treatment option.

It is not known if AUGTYRO is safe and effective in children with ROS1-positive NSCLC or in children younger than 12 years of age with NTRK-positive solid tumors.

IMPORTANT SAFETY INFORMATION
AUGTYRO® (repotrectinib) may cause serious side effects, including:

Central nervous system (CNS) effects. Tell your healthcare provider right away if you experience any new or worsening symptoms of CNS effects during treatment with AUGTYRO, including:

  • dizziness
  • vertigo
  • changes in mood, such as anxiety, irritability, and depression
  • balance or coordination problems
  • problems with thinking, such as forgetfulness or confusion
  • seeing or hearing things that are not real (hallucinations)
  • problems with concentration, attention, memory, and sleep

Lung problems (pneumonitis). Tell your healthcare provider right away if you have any new or worsening lung problems, including a dry cough (without mucus), productive cough (with mucus), wheezing, or trouble breathing.

Liver problems. Your healthcare provider will do blood tests to check your liver function before starting treatment with AUGTYRO, every 2 weeks for the first month and as needed during treatment. Tell your healthcare provider right away if you develop symptoms of liver problems including: your skin or the white part of your eyes turns yellow, dark or “tea-colored” urine, light-colored stools (bowel movements), loss of appetite, nausea or vomiting, pain on the upper right side of your stomach area.

Muscle problems. Your healthcare provider will do blood tests before starting treatment with AUGTYRO, every 2 weeks for the first month and as needed during treatment. Tell your healthcare provider right away if you get new or worsening signs and symptoms of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness.

Increased uric acid level in your blood (hyperuricemia). AUGTYRO may cause an excess of uric acid in your blood. Your healthcare provider will do tests before and during your treatment with AUGTYRO to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels. Tell your healthcare provider if you experience symptoms of increased uric acid including:

  • red, hot, tender, or swollen joints, especially in your big toe
  • pain in your stomach-area or sides
  • decrease in your amount of urine or no urine at all
  • nausea or vomiting
  • pink or brown urine or blood in your urine

Bone fractures. AUGTYRO may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider right way if you have pain, changes in movement, or bone abnormalities.

Before taking AUGTYRO, tell your healthcare provider about all your medical conditions, including if you:

  • have nervous system (neurological) problems.
  • have lung or breathing problems other than lung cancer.
  • have liver or kidney problems
  • are pregnant or plan to become pregnant. AUGTYRO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with AUGTYRO.
  • Females who are able to become pregnant:

    • Your healthcare provider should do a pregnancy test before you start treatment with AUGTYRO.
    • You should use effective non-hormonal birth control (contraception) during treatment and for 2 months after the last dose of AUGTYRO.
    • Birth control methods that contain hormones (such as birth control pills, injections or transdermal system patches) may not work as well during treatment with AUGTYRO.
    • Talk to your healthcare provider about birth control methods that may be right for you.

    Male patients with female partners who are able to become pregnant:

    • You should use effective birth control during treatment with AUGTYRO and for 4 months after the last dose.
  • are breastfeeding or plan to breastfeed. It is not known if AUGTYRO passes into your breast milk. Do not breastfeed during treatment and for 10 days after the last dose of AUGTYRO. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.

Taking AUGTYRO with certain other medicines may affect the amount of AUGTYRO or other medicines in your blood and may cause side effects or affect the way that AUGTYRO or other medicines work. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What should I avoid while taking AUGTYRO?

  • You should not drink grapefruit juice or eat grapefruit during your treatment with AUGTYRO. It may increase the amount of AUGTYRO in your blood to a harmful level.
  • Do not drive or operate machinery until you know how AUGTYRO affects you. If you experience dizziness, blurred vision, memory loss, changes in mental status, confusion, hallucinations or have trouble with balance or coordination or problems with concentration and attention, do not drive or operate machinery until your symptoms have resolved.

The most common side effects of AUGTYRO include: dizziness; change in sense of taste; feeling of numbness or tingling in your arms or legs; constipation; shortness of breath; tiredness; trouble with balance, coordination, and walking; problems with thinking, such as forgetfulness or confusion, memory problems and hallucinations; muscle weakness; and nausea.

These are not all the possible side effects of AUGTYRO.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see U.S. Full Prescribing Information and Patient Information for AUGTYRO.

© 2024 Turning Point Therapeutics, Inc., a Bristol Myers Squibb company.

AUGTYRO® and the respective logo are trademarks of Turning Point Therapeutics, Inc.

BMS Access Support® is a registered trademark of Bristol-Myers Squibb Company.

3600-US-2400130 06/24

IMPORTANT SAFETY INFORMATION
Indication

AUGTYRO® (repotrectinib) is a prescription medicine used to treat:

  • adults with non-small cell lung cancer (NSCLC) that has spread within your chest or to other parts of the body and is caused by an abnormal ROS1 gene.
  • adults and children 12 years of age and older with solid tumors (cancer) that:
    • are caused by certain abnormal NTRK genes, and
    • have spread to other parts of the body, or if surgery to remove your cancer is likely to cause severe complications, and
    • have grown or spread after other treatment or there is no satisfactory alternative treatment option.

It is not known if AUGTYRO is safe and effective in children with ROS1-positive NSCLC or in children younger than 12 years of age with NTRK-positive solid tumors.

AUGTYRO™ (repotrectinib) may cause serious side effects, including:

Central nervous system (CNS) effects. AUGTYRO may cause dizziness, balance, or coordinator problems, may affect how you think, cause confusion, hallucinations, problems with concentration, attention, and memory. Tell your healthcare provider right away if you have any of these symptoms.

This website is best viewed using the vertical display on your mobile device.

This website is best viewed using the horizontal display on your tablet device.